PCSK9 inhibitors: smooth sailing or a little turbulence ahead?

被引:1
作者
Hegele, Robert A. [1 ,2 ,3 ]
机构
[1] Robarts Res Inst, London, ON N6A 5B7, Canada
[2] Western Univ, Schulich Sch Med & Dent, Dept Med, London, ON, Canada
[3] Western Univ, Schulich Sch Med & Dent, Dept Biochem, London, ON, Canada
基金
加拿大健康研究院;
关键词
ACUTE CORONARY SYNDROMES; BOCOCIZUMAB; ALIROCUMAB; ANTIBODY; EFFICACY; SAFETY; RISK;
D O I
10.1016/S2213-8587(17)30150-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:490 / 492
页数:4
相关论文
共 10 条
  • [1] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    Cannon, Christopher P.
    Blazing, Michael A.
    Giugliano, Robert P.
    McCagg, Amy
    White, Jennifer A.
    Theroux, Pierre
    Darius, Harald
    Lewis, Basil S.
    Ophuis, Ton Oude
    Jukema, J. Wouter
    De Ferrari, Gaetano M.
    Ruzyllo, Witold
    De Lucca, Paul
    Im, KyungAh
    Bohula, Erin A.
    Reist, Craig
    Wiviott, Stephen D.
    Tershakovec, Andrew M.
    Musliner, Thomas A.
    Braunwald, Eugene
    Califf, Robert M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) : 2387 - 2397
  • [2] Interpretation of the evidence for the efficacy and safety of statin therapy
    Collins, Rory
    Reith, Christina
    Emberson, Jonathan
    Armitage, Jane
    Baigent, Colin
    Blackwell, Lisa
    Blumenthal, Roger
    Danesh, John
    Smith, George Davey
    DeMets, David
    Evans, Stephen
    Law, Malcolm
    MacMahon, Stephen
    Martin, Seth
    Neal, Bruce
    Poulter, Neil
    Preiss, David
    Ridker, Paul
    Roberts, Ian
    Rodgers, Anthony
    Sandercock, Peter
    Schulz, Kenneth
    Sever, Peter
    Simes, John
    Smeeth, Liam
    Wald, Nicholas
    Yusuf, Salim
    Peto, Richard
    [J]. LANCET, 2016, 388 (10059) : 2532 - 2561
  • [3] Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
    Koren, Michael J.
    Sabatine, Marc S.
    Giugliano, Robert P.
    Langslet, Gisle
    Wiviott, Stephen D.
    Kassahun, Helina
    Ruzza, Andrea
    Ma, Yuhui
    Somaratne, Ransi
    Raal, Frederick J.
    [J]. JAMA CARDIOLOGY, 2017, 2 (06) : 598 - 607
  • [4] Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
    Ray, Kausik K.
    Landmesser, Ulf
    Leiter, Lawrence A.
    Kallend, David
    Dufour, Robert
    Karakas, Mahir
    Hall, Tim
    Troquay, Roland P. T.
    Turner, Traci
    Visseren, Frank L. J.
    Wijngaard, Peter
    Wright, R. Scott
    Kastelein, John J. P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (15) : 1430 - 1440
  • [5] Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
    Ridker, P. M.
    Revkin, J.
    Amarenco, P.
    Brunell, R.
    Curto, M.
    Civeira, F.
    Flather, M.
    Glynn, R. J.
    Gregoire, J.
    Jukema, J. W.
    Karpov, Y.
    Kastelein, J. J. P.
    Koenig, W.
    Lorenzatti, A.
    Manga, P.
    Masiukiewicz, U.
    Miller, M.
    Mosterd, A.
    Murin, J.
    Nicolau, J. C.
    Nissen, S.
    Ponikowski, P.
    Santos, R. D.
    Schwartz, P. F.
    Soran, H.
    White, H.
    Wright, R. S.
    Vrablik, M.
    Yunis, C.
    Shear, C. L.
    Tardif, J. -C.
    Conde, Diego
    Colquhoun, David
    Missault, Luc
    Gregoire, Jean
    Gao, Runlin
    Urina, Miguel
    Solar, Miroslav
    Jensen, Henrik Kjaerulf
    Grobbee, Diederick
    Savolainen, Markku
    Schiele, Francois
    Montalescot, Gilles
    Edes, Istvan
    Blake, Gavin
    Lotan, Chaim
    Maggioni, Aldo
    Savonitto, Stefano
    Lee, Cheol Whan
    Leiva Pons, Jose Luis
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16) : 1527 - 1539
  • [6] Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
    Ridker, Paul M.
    Tardif, Jean-Claude
    Amarenco, Pierre
    Duggan, William
    Glynn, Robert J.
    Jukema, J. Wouter
    Kastelein, John J. P.
    Kim, Albert M.
    Koenig, Wolfgang
    Nissen, Steven
    Revkin, James
    Rose, Lynda M.
    Santos, Raul D.
    Schwartz, Pamela F.
    Shear, Charles L.
    Yunis, Carla
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16) : 1517 - 1526
  • [7] Antidrug Antibodies in Patients Treated with Alirocumab
    Roth, Eli M.
    Goldberg, Anne C.
    Catapano, Alberico L.
    Torri, Albert
    Yancopoulos, George D.
    Stahl, Neil
    Brunet, Aurelie
    Lecorps, Guillaume
    Colhoun, Helen M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16) : 1589 - 1590
  • [8] Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.1056/NEJMoa1615664, 10.4997/JRCPE.2017.212]
  • [9] Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
    Sabatine, Marc S.
    Giugliano, Robert P.
    Wiviott, Stephen D.
    Raal, Frederick J.
    Blom, Dirk J.
    Robinson, Jennifer
    Ballantyne, Christie M.
    Somaratne, Ransi
    Legg, Jason
    Wasserman, Scott M.
    Scott, Robert
    Koren, Michael J.
    Stein, Evan A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (16) : 1500 - 1509
  • [10] Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
    Schwartz, Gregory G.
    Bessac, Laurence
    Berdan, Lisa G.
    Bhatt, Deepak L.
    Bittner, Vera
    Diaz, Rafael
    Goodman, Shaun G.
    Hanotin, Corinne
    Harrington, Robert A.
    Jukema, J. Wouter
    Mahaffey, Kenneth W.
    Moryusef, Angele
    Pordy, Robert
    Roe, Matthew T.
    Rorick, Tyrus
    Sasiela, William J.
    Shirodaria, Cheerag
    Szarek, Michael
    Tamby, Jean-Francois
    Tricoci, Pierluigi
    White, Harvey
    Zeiher, Andreas
    Steg, Philippe Gabriel
    [J]. AMERICAN HEART JOURNAL, 2014, 168 (05) : 682 - 689